| Field | Specification |
|---|---|
| Target | |
| Alternative names | Denticleless protein homolog; DDB1- and CUL4-associated factor 2; Lethal(2) denticleless protein homolog; Retinoic acid-regulated nuclear matrix-associated protein; DTL; CDT2; CDW1; DCAF2; L2DTL; RAMP |
| Gene ID | |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | A synthesized peptide derived from human CDT2 Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis. The DCX (DTL) complex, also named CRL4 (CDT2) complex, mediates the polyubiquitination and subsequent degradation of CDT1 and CDKN1A/p21 (CIP1) . |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Liquid |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone AEBD-4 is a rabbit monoclonal antibody that recognizes denticleless protein homolog (gene DTL) in human, mouse and rat samples and is validated for Western blot, IHC, ICC/IF and flow cytometry. The predicted molecular weight is 79.5 kDa, and the supplier reports an observed band at about 95 kDa.
DTL (also called CDT2) is the substrate receptor of the CRL4CDT2 ubiquitin ligase. It targets proteins such as CDT1, p21 and SET8 for degradation after PCNA loading, helping prevent DNA re-replication, and it is studied in cell cycle control and the DNA damage response.
| Target | Denticleless protein homolog (gene DTL; UniProt Q9NZJ0, human) |
|---|---|
| Clone | AEBD-4 |
| Host / Clonality / Isotype | Rabbit / Monoclonal / Rabbit IgG |
| Reactivity | Human, Mouse, Rat |
| Form | Liquid |
| Formulation | PBS (pH 7.4); 150 mM NaCl; 0.02% sodium azide; 50% glycerol; plus stabilizers |
| Calculated MW | 79.5 kDa |
| Observed MW | 95 kDa |
| Storage | Long term: −20 °C for up to 12 months. Frequent use: 4 °C for up to 1 month. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 1:500–1:2000 |
|---|---|
| Immunohistochemistry | 1:50–1:200 |
| Immunocytochemistry / Immunofluorescence | 1:50–1:200 |
| Flow cytometry | 1:80 |
Samples with a confirmed band (WB): human 293T cells, human SH-SY5Y cells, human K562 cells, rat testis tissue, rat thymus tissue, mouse testis tissue, mouse thymus tissue.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 1:500 overnight at 4 °C, HRP-conjugated secondary antibody at 1:500, ECL detection.
Immunogen
Synthetic peptide based on the sequence of human CDT2 Substrate-specific adapter of a DCX (DDB1-CUL4-X-box) E3 ubiquitin-protein ligase complex required for cell cycle control, DNA damage response and translesion DNA synthesis.
Reactivity Notes
The supplier lists reactivity with human, mouse and rat. UniProt places denticleless protein homolog in the nucleus, nuclear membrane, nucleoplasmic side and chromosome. Tissue expression noted by UniProt (human): Expressed in placenta and testis, very low expression seen in skeletal muscle. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
